A Viral Protein 4-Based Trivalent Nanoparticle Vaccine Elicited High and Broad Immune Responses and Protective Immunity against the Predominant Rotaviruses

Abstract

The current live rotavirus (RV) vaccines show reduced effectiveness in developing countries, calling for vaccine strategies with improved efficacy and safety. We generated pseudovirus nanoparticles (PVNPs) that display multiple ectodomains of RV viral protein 4 (VP4), named S-VP4e, as a nonreplicating RV vaccine candidate. The RV spike protein VP4s that bind host receptors and facilitate viral entry are excellent targets for vaccination. In this study, we developed scalable methods to produce three S-VP4e PVNPs, each displaying the VP4e antigens from one of the three predominant P[8], P[4], and P[6] human RVs (HRVs). These PVNPs were recognized by selected neutralizing VP4-specific monoclonal antibodies, bound glycan receptors, attached to permissive HT-29 cells, and underwent cleavage by trypsin between VP8* and VP5*. 3D PVNP models were constructed to understand their structural features. A trivalent PVNP vaccine containing the three S-VP4e PVNPs elicited high and well-balanced VP4e-specific antibody titers in mice directed against the three predominant HRV P types. The resulting antisera neutralized the three HRV prototypes at high titers; greater than 4-fold higher than the neutralizing responses induced by a trivalent vaccine consisting of the S 60 -VP8* PVNPs. Finally, the trivalent S-VP4e PVNP vaccine provided 90−100% protection against diarrhea caused by HRV challenge. Our data supports the trivalent S-VP4e PVNPs as a promising nonreplicating HRV vaccine candidate for parenteral delivery to circumvent the suboptimal immunization issues of all present live HRV vaccines. The established PVNP-permissive cell and PVNP-glycan binding assays will be instrumental for further investigating HRV−host cell interactions and neutralizing effects of VP4-specific antibodies and antivirals.

Human milk antibodies to global pathogens reveal geographic and interindividual variations in IgA and IgG

“…It is interesting that the most significant IgA response associated with delay to infection was the Rotavirus A VP4 outer capsid protein. VP4 is a spike protein proteolytically cleaved into VP5* and VP8* subunits before the virus can be activated ( 54 ), the latter a subunit vaccine candidate ( 55 – 58 ) as well as targeted regions of VP4 ( 59 , 60 ). Neutralizing antibodies have been identified for both VP4* and VP8* ( 61 , 62 ), as well as resistance to challenge ( 63 ).…”